

Edgar Filing: CYTOGEN CORP - Form 10-Q

CYTOGEN CORP
Form 10-Q
August 14, 2002

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13
OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
1934

For the quarterly period ended June 30, 2002

OR

TRANSITION REPORT PURSUANT TO SECTION 13
OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
1934

For the transition period from _____ to _____

Commission file number 000-14879

Cytogen Corporation

(Exact name of Registrant as specified in its charter)

Delaware

22-2322400

(State or Other Jurisdiction of
Incorporation or Organization)

(I.R.S. Employer
Identification Number)

600 College Road East, CN 5308, Princeton, NJ 08540-5308

(Address of Principal Executive Offices and Zip Code)

Registrant's telephone number, including area code (609) 750-8200

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days: Yes X No .

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date:

Class	Outstanding at August 1, 2002
-----	-----
Common Stock, \$.01 par value	86,772,525

Edgar Filing: CYTOGEN CORP - Form 10-Q

PART I - FINANCIAL INFORMATION

Item 1 - Consolidated Financial Statements

CYTOGEN CORPORATION AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(All amounts in thousands, except share data)
(Unaudited)

	June 30, 2002	December 31, 2001
	-----	-----
ASSETS:		
Current Assets:		
Cash and cash equivalents	\$ 18,902	\$ 11,309
Marketable securities	837	1,376
Receivable on income tax benefit sold	-	1,103
Accounts receivable, net	1,852	1,621
Inventories	1,371	1,889
Other current assets	760	508
	-----	-----
Total current assets	23,722	17,806
Property and Equipment, net	1,535	1,831
Other Assets	2,614	1,855
	-----	-----
	\$ 27,871	\$ 21,492
	=====	=====
LIABILITIES AND STOCKHOLDERS' EQUITY:		
Current Liabilities:		
Current portion of long-term debt	\$ 106	\$ 77
Accounts payable and accrued liabilities	4,588	5,315
Accrued stock liability	2,000	-
Deferred revenue	260	534
	-----	-----
Total current liabilities	6,954	5,926
	-----	-----
Long-Term Debt	2,400	2,291
	-----	-----
Deferred Revenue	2,055	2,061
	-----	-----
Stockholders' Equity:		
Preferred stock, \$.01 par value, 5,400,000 shares authorized - Series C Junior Participating Preferred Stock, \$.01 par value, 200,000 shares authorized, none issued and outstanding	-	-
Common stock, \$.01 par value, 250,000,000 shares authorized, 86,271,000 and 78,937,000 shares issued and outstanding at June 30, 2002 and December 31, 2001, respectively	863	789
Additional paid-in capital	364,531	350,867
Deferred compensation	(367)	(621)

Edgar Filing: CYTOGEN CORP - Form 10-Q

Accumulated other comprehensive income	321	860
Accumulated deficit	(348,886)	(340,681)
	-----	-----
Total stockholders' equity	16,462	11,214
	-----	-----
	\$ 27,871	\$ 21,492
	=====	=====

The accompanying notes are an integral part of these statements.

2

CYTOGEN CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
(All amounts in thousands, except per share data)
(Unaudited)

	Three Months Ended June 30,		Six Months Ended June	
	2002	2001	2002	
	-----	-----	-----	-----
Revenues:				
Product related:				
ProstaScint	\$ 1,971	\$ 1,789	\$ 4,047	\$
BrachySeed	565	70	1,017	
OncoScint	56	145	110	
	-----	-----	-----	-----
Total product sales	2,592	2,004	5,174	
Quadramet royalties	510	595	1,009	
	-----	-----	-----	-----
Total product related	3,102	2,599	6,183	
License and contract revenues	65	257	280	
	-----	-----	-----	-----
Total revenues	3,167	2,856	6,463	
	-----	-----	-----	-----
Operating Expenses:				
Cost of product sales.....	1,241	644	2,295	
Research and development	1,746	2,483	5,545	
Equity loss in PSMA LLC	595	-	1,108	
Selling and marketing	1,622	1,577	3,075	
General and administrative	1,200	1,349	2,710	
	-----	-----	-----	-----
Total operating expenses	6,404	6,053	14,733	1
	-----	-----	-----	-----
Operating loss	(3,237)	(3,197)	(8,270)	(
Interest income	72	156	149	

Edgar Filing: CYTOGEN CORP - Form 10-Q

Interest expense	(42)	(44)	(84)	
	-----	-----	-----	-----
Net loss	\$ (3,207)	\$ (3,085)	\$ (8,205)	\$ (
	=====	=====	=====	=====
Basic and diluted net loss per share	\$ (0.04)	\$ (0.04)	\$ (0.10)	\$
	=====	=====	=====	=====
Weighted average common shares outstanding	83,082	77,444	82,172	7
	=====	=====	=====	=====

The accompanying notes are an integral part of these statements.

3

CYTOGEN CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(All amounts in thousands)
(Unaudited)

	Six Months Ended June 30,	
	2002	2001
	-----	-----
CASH FLOWS FROM OPERATING ACTIVITIES:		
Net loss	\$ (8,205)	\$ (5,739)
Adjustments to reconcile net loss to net cash used in operating activities:		
Depreciation and amortization	407	580
Imputed interest	-	(22)
Stock-based compensation expenses	747	257
Amortization of deferred revenue	(280)	(430)
Stock-based milestone charge	2,000	-
Changes in assets and liabilities:		
Receivables, net	872	(348)
Inventories	518	(979)
Other assets	(511)	830
Accounts payable and accrued liabilities	(462)	(1,219)
	-----	-----
Net cash used in operating activities	(4,914)	(7,070)
	-----	-----
CASH FLOWS FROM INVESTING ACTIVITIES:		
Purchase of product rights	(500)	-
Net proceeds from sale of equipment	100	-
Purchases of property and equipment	(24)	(303)
	-----	-----
Net cash used in investing activities	(424)	(303)
	-----	-----
CASH FLOWS FROM FINANCING ACTIVITIES:		
Proceeds from issuance of common stock	12,980	14,201
Payment of long-term debt	(49)	(108)
	-----	-----

Edgar Filing: CYTOGEN CORP - Form 10-Q

Net cash provided by financing activities	12,931	14,093
	-----	-----
Net increase in cash and cash equivalents	7,593	6,720
Cash and cash equivalents, beginning of period	11,309	11,993
	-----	-----
Cash and cash equivalents, end of period	\$ 18,902	\$ 18,713
	=====	=====

The accompanying notes are an integral part of these statements.

4

CYTOGEN CORPORATION AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

1. THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES:

The Company

Cytogen Corporation ("Cytogen" or the "Company") is a biopharmaceutical company with an established and growing product line in prostate cancer and other areas of oncology. FDA-approved products include ProstaScint(R) (a monoclonal antibody-based imaging agent used to image the extent and spread of prostate cancer); BrachySeed(TM) I-125 and Pd-103, (uniquely designed, next-generation radioactive seed implants for the treatment of localized prostate cancer); and Quadramet(R) (a therapeutic agent marketed for the relief of bone pain in prostate and other types of cancer). Cytogen is evolving a pipeline of oncology product candidates by developing its prostate specific membrane antigen, or PSMA technologies, which are exclusively licensed from Memorial Sloan-Kettering Cancer Center.

AxCell Biosciences Corporation, a subsidiary of Cytogen Corporation, is engaged in the research and development of novel biopharmaceutical products using its portfolio of functional proteomics solutions and collection of proprietary signal transduction pathway information. Through the systematic and industrialized measurement of protein-to-protein interactions, AxCell is assembling ProChart(TM), a proprietary database of signal transduction pathway information that is relevant in a number of therapeutically important classes of molecules including growth factors, receptors and other potential protein therapeutics or drug targets. AxCell's database content and functional proteomics tools are available on a non-exclusive basis to biotechnology, pharmaceutical and academic researchers. AxCell is continuing its research activities to further elucidate the role of novel proteins through both external collaborations and data mining.

Basis of Consolidation

The consolidated financial statements include the accounts of Cytogen and its subsidiaries. Intercompany balances and transactions have been eliminated in consolidation.

Basis of Presentation

Edgar Filing: CYTOGEN CORP - Form 10-Q

The consolidated financial statements and notes thereto of Cytogen are unaudited and include all adjustments, which in the opinion of management, are necessary to present fairly the financial condition and results of operations as of and for the periods set forth in the Consolidated Balance Sheets, Consolidated Statements of Operations and Consolidated Statements of Cash Flows. All such accounting adjustments are of a normal, recurring nature. The consolidated financial statements do not include all of the information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles and should be read in

5

conjunction with the consolidated financial statements and notes thereto included in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission, which includes financial statements as of and for the year ended December 31, 2001. The results of the Company's operations for any interim period are not necessarily indicative of the results of the Company's operations for any other interim period or for a full year.

Cash and Cash Equivalents

Cash and cash equivalents include cash on hand, cash in banks and all highly-liquid investments with a maturity of three months or less at the time of purchase.

Marketable Securities

In connection with the acquisition of Prostagin Inc. in June 1999, the Company received 275,350 shares of Northwest Biotherapeutics, Inc. common stock. The Company has classified this investment as available-for-sale securities in accordance with Statement of Financial Accounting Standards ("SFAS") No. 115, "Accounting for Certain Investments in Debt and Equity Securities." Available-for-sale securities are carried at fair value, based on quoted market prices, with unrealized gains or losses reported as a separate component of stockholders' equity. As of June 30, 2002 and December 31, 2001, the Company had unrealized gains of \$321,000 and \$860,000, respectively, related to this investment. There is no assurance, however that the Company can sell these securities within a reasonable amount of time without negatively affecting the price of the stock since the daily trading volume has been low.

Inventories

The Company's inventories are primarily related to ProstaScint and OncoScint CR/OV. Inventories are stated at the lower of cost or market using the first-in, first-out method and consisted of the following:

	June 30, 2002	December 31, 2001
	-----	-----
Raw materials.....	\$ 506,000	\$ 506,000
Work-in process.....	24,000	1,371,000
Finished goods.....	841,000	12,000
	-----	-----
	\$1,371,000	\$1,889,000
	=====	=====

Edgar Filing: CYTOGEN CORP - Form 10-Q

Comprehensive Income (Loss)

SFAS No. 130, "Reporting Comprehensive Income" ("SFAS 130") requires reporting and displaying comprehensive income (loss) and its components which, for the Company, include net loss and unrealized gains or losses on available for sale marketable securities. In accordance with SFAS 130, the accumulated balance of other comprehensive income or loss is displayed as a separate

6

component of stockholders' equity. The following table reconciles net loss to comprehensive loss for the three and six months ended June 30, 2002.

	Three Months Ended June 30, 2002	Six Months Ended June 30, 2002
	-----	-----
Net loss.....	\$(3,207,000)	\$(8,205,000)
Other comprehensive loss:		
Unrealized losses on available for sale marketable securities.....	(223,000)	(539,000)
	-----	-----
Comprehensive loss.....	\$(3,430,000)	\$(8,744,000)
	=====	=====

During the three and six months ended June 30, 2001, the Company had no unrealized gains or losses on marketable securities.

Net Loss Per Share

Basic net loss per share is based upon the weighted average common shares outstanding during each period. Diluted net loss per share is the same as basic net loss per share, as the inclusion of common stock equivalents would be antidilutive.

Reclassifications

Certain reclassifications have been made to the 2001 financial statements to conform to the 2002 presentation.

2. EQUITY LOSS IN PSMA DEVELOPMENT CO. LLC:

In June 1999, Cytogen entered into a joint venture called the PSMA Development Co. LLC (the "Joint Venture"), with Progenics Pharmaceuticals Inc. ("Progenics"), to develop vaccine and antibody-based immunotherapeutic products utilizing Cytogen's exclusively licensed PSMA technology. The Joint Venture is owned equally by Cytogen and Progenics. The Company accounts for the Joint Venture using the equity method of accounting. Progenics was obligated to fund the initial \$3.0 million of development costs of the Joint Venture. Beginning in December 2001, the Company and Progenics began to equally share the costs of the Joint Venture. Since December 2001, Cytogen has recognized 50% of the Joint Venture's operating results in its consolidated results of operations. Selected financial statement information of the Joint Venture is as follows:

Statement of Operations Data:

Edgar Filing: CYTOGEN CORP - Form 10-Q

	Three Months Ended June 30,		Six Months Ended June 30,	
	2002	2001	2002	2001
Interest income.....	\$ 4,000	\$ 11,000	\$ 4,000	\$ 26,000
Total expenses.....	1,193,000	594,000	2,220,000	1,035,000
Net loss.....	<u>\$ (1,189,000)</u>	<u>\$ (583,000)</u>	<u>\$ (2,216,000)</u>	<u>\$ (1,009,000)</u>

7

3. SALES OF CYTOGEN COMMON STOCK:

In January 2002, the Company sold 2,970,665 shares of Cytogen common stock to the State of Wisconsin Investment Board ("SWIB"), for an aggregate purchase price of \$8.0 million or \$2.69 per share, pursuant to a January 2002 Share Purchase Agreement between SWIB and the Company. In June 2002, the Company sold an additional 4,166,700 shares of Cytogen common stock to SWIB for an aggregate purchase price of \$5.0 million or \$1.20 per share. Pursuant to its agreements with SWIB, in January 2002 the Company agreed not to enter into equity line arrangements in the future, issue certain securities at less than fair market value or undertake certain other securities issuances without requisite stockholder approval.

4. AMENDMENT OF AGREEMENT AND MILESTONE PAYMENTS:

Pursuant to a Stock Exchange Agreement ("Prostagen Agreement") related to the acquisition of Prostagen Inc. ("Prostagen") in June 1999, the Company agreed to issue up to an additional \$4.0 million worth of Cytogen common stock to the shareholders and debtholders of Prostagen, if certain milestones are achieved in the dendritic cell therapy and PSMA development programs. During the first quarter of 2002, the Company and former Prostagen shareholders agreed that a milestone was achieved based on the progress of the dendritic cell prostate cancer clinical trials at Northwest Biotherapeutics, Inc. As a result, the Company accrued a \$2.0 million stock liability with a corresponding charge recorded as research and development expense in the first quarter of 2002. In May 2002, the Company entered into an addendum to the Prostagen Agreement (the "Addendum") which clarifies the milestone payments to be made under the Prostagen Agreement, as well as the timing of such payments. Pursuant to the Addendum, Cytogen will issue and register with the Securities and Exchange Commission (the "SEC") \$2.0 million worth of Cytogen common stock, or 1,226,994 shares in satisfaction of the stock liability. In addition, the Company may be obligated to pay two additional milestone payments of \$1.0 million each, upon the earlier of certain clinical achievements regarding the PSMA development programs or January 2003 and July 2003, respectively, provided that the payments shall be due on these dates only if safety has been established in a completed Phase I clinical trial and the research program on immunotherapy for prostate cancer is continuing on such dates. Any future milestone payments are payable in shares of Cytogen common shares which will be registered with the SEC after issuance.

Under the terms of a Product, Manufacturing and Supply Agreement entered in December 2000 between Cytogen and Draximage Inc., Draximage will supply radioactive iodine and palladium seeds to Cytogen in exchange for product transfer payments, royalties on sales and certain milestone payments. Pursuant to the agreement, Cytogen is obligated to pay Draximage \$1.0 million upon the first sale of BrachySeed Pd-103, which occurred in May 2002. As of June 30,

Edgar Filing: CYTOGEN CORP - Form 10-Q

2002, the Company paid \$500,000 of this milestone and has accrued the remaining balance which will be paid at a later date. The Company has recorded the \$1.0 million milestone in other assets in the accompanying consolidated balance sheet as of June 30, 2002 and will amortize it over the approximately eight year remaining term of the Draximage agreement.

8

Item 2 - Management's Discussion and Analysis of Financial Condition and Results of Operations

The following discussion contains historical information as well as forward looking statements that involve a number of risks and uncertainties. Statements contained or incorporated by reference in this Quarterly Report on Form 10-Q that are not based on historical facts are "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Generally, forward looking statements can be identified by the use of phrases like "believe", "expect", "anticipate", "plan", "may", "will", "could", "estimate", "potential", "opportunity" and "project" and similar terms. The Company's actual results could differ materially from the Company's historical results of operations and those discussed in the forward looking statements. Factors that could cause actual results to differ materially, include, but are not limited to those identified in the Company's Annual Report on Form 10-K for the year ended December 31, 2001 under the caption "Additional Factors That May Affect Future Results". Investors are cautioned not to put undue reliance on any forward looking statement.

Cautionary Statement

In addition to the risks discussed under the caption referred to above, among other factors that could cause actual results to differ materially from expected results are the following: (i) the Company's ability to access the capital markets in the near term and in the future for continued funding of its operations including the continued listing of the Company's common stock on the Nasdaq National Market; (ii) the ability to attract and retain personnel needed for business operations and strategic plans; (iii) the timing and results of clinical studies, and regulatory approvals; (iv) market acceptance of the Company's products, including programs designed to facilitate use of the products, such as the Partners in Excellence or PIE Program; (v) demonstration over time of the efficacy and safety of the Company's products; (vi) the degree of competition from existing or new products; (vii) the decision by the majority of public and private insurance carriers on whether to reimburse patients for the Company's products; (viii) the ability of the Company and its partners to comply with applicable governmental regulations and changes thereto; (ix) the profitability of its products; (x) the ability to attract, and the ultimate success of, strategic partnering arrangements, collaborations, and acquisition candidates; (xi) the ability of the Company and its partners to identify new products as a result of those collaborations that are capable of achieving FDA approval, that are cost-effective alternatives to existing products and that are ultimately accepted by the key users of the product; (xii) the ability to integrate the in-licensed products such as BrachySeed; (xiii) the success of the Company in obtaining marketing approvals for its products in Canada and Europe; (xiv) the ability of the Company to protect its proprietary technology, trade secrets or know-how under the patent and other intellectual property laws of the United States and other countries; and (xv) the ability of Advanced Magnetics Inc. to satisfy the conditions specified by the FDA regarding approval to market Combimedex in the United States.

Edgar Filing: CYTOGEN CORP - Form 10-Q

The following discussion and analysis should be read in conjunction with the Financial Statements and related notes thereto contained elsewhere herein, as well as the Company's Annual Report on Form 10-K for the year ended December 31, 2001 and from time to time the Company's other filings with the Securities and Exchange Commission.

9

Significant Events in 2002

During May 2002, the Company launched the palladium version of BrachySeed(TM) (Pd-103), a uniquely designed next generation radioactive seed implant for the treatment of localized prostate cancer. The Company introduced the iodine version of BrachySeed (I-125) in 2001, and since then has increased its penetration of the brachytherapy iodine market, resulting in consistent quarter-over-quarter growth in BrachySeed sales. Despite such historical quarter-over-quarter sales increase, there can be no assurance that such increase will continue in the future. The Company is utilizing its existing oncology sales force to market both BrachySeed products.

Also in 2002, the Company received regulatory approval in Canada for ProstaScint(R), the Company's radio-labeled monoclonal antibody prostate cancer imaging agent. ProstaScint was approved for marketing in the United States in 1996. In both Canada and the United States, ProstaScint is indicated for use in patients newly diagnosed with prostate cancer who are at risk for lymph node metastases and for patients with recurrent prostate cancer following a radical prostatectomy who are suspected of having occult metastatic disease. In Canada, ProstaScint is also indicated for use in identifying those patients with recurrent prostate cancer who are likely to benefit from receiving local salvage radiation therapy. The Company plans to launch both ProstaScint and Quadramet in Canada, alone or with a partner during 2002. Quadramet, which was approved for marketing in Canada in 1998, is a therapeutic agent marketed in the U.S. for the relief of bone pain in prostate and other types of cancer. There can be no assurance, however, regarding the timing of launch for ProstaScint and Quadramet in Canada, the market acceptance of the newly launched products including BrachySeed I-125 and Pd-103 and whether these products will significantly increase the revenues of the Company.

The Company is currently exploring strategic alternatives for its subsidiary, AxCell BioSciences Corporation ("AxCell"), that would allow the Company to reduce its cash expenditures relating to AxCell in order to leverage its oncology franchise. AxCell is engaged in the research and development of novel biopharmaceutical products using its portfolio of functional proteomics solutions and collection of proprietary signal transduction pathway information. The Company expects to complete its review of these strategic alternatives by the end of the third quarter of 2002.

Results of Operations

Three Months Ended June 30, 2002 and 2001

Revenues. Total revenues for the second quarter of 2002 were \$3.2 million compared to \$2.9 million for the same period in 2001. The increase from the prior year period is due to higher product related revenues, partially offset by lower license and contract revenues. Product related revenues, which included product sales and royalties, accounted for 98% and 91% of total revenues for the second quarters of 2002 and 2001, respectively. License and contract revenues accounted for the remainder of revenues.

Product related revenues for the second quarter of 2002 were \$3.1 million

Edgar Filing: CYTOGEN CORP - Form 10-Q

compared to \$2.6 million for the same period in 2001. Sales of ProstaScint accounted for 64% and 69% of product related revenues in the second quarters of 2002 and 2001, respectively, while Quadramet royalties accounted for 16% and 23%

10

of product related revenues for such quarters, respectively. Sales of ProstaScint were \$2.0 million for the second quarter of 2002, \$182,000 higher than the \$1.8 million recorded in the second quarter of 2001. Future growth of ProstaScint is dependent upon increased marketing and sales initiatives by Cytogen's in-house sales force, entry in additional markets and the implementation of new product applications, such as using ProstaScint scans to guide the placement of brachytherapy seeds and/or external beam radiation. There can be no assurance, however, that such initiatives will significantly increase the sales of ProstaScint.

Sales of BrachySeed during the second quarter of 2002 were \$565,000 and accounted for 18% of product related revenues, compared to \$70,000 recorded in the same period of 2001. Since the market introduction of BrachySeed I-125 in February 2001, the Company has increased its penetration of the brachytherapy iodine market resulting in consistent quarter-over-quarter growth. BrachySeed sales in 2002 also include the initial sale of BrachySeed Pd-103, which was launched in May 2002. There can be no assurance, however, as to the market acceptance of the BrachySeed I-125 and Pd-103 or whether the sale of these products will significantly increase the revenues of the Company.

Sales of OncoScint CR/OV during the second quarter of 2002 were \$56,000 compared to \$145,000 in the same period of 2001. The market for OncoScint CR/OV for colorectal cancer diagnosis has been negatively affected by positron emission tomography or "PET" scans which have shown the same or higher sensitivity than OncoScint CR/OV. Accordingly, the Company is decreasing its emphasis on OncoScint in order to focus on its prostate cancer products.

Quadramet royalties for the second quarter of 2002 were \$510,000, \$85,000 less than the \$595,000 reported in the same period of 2001. Quadramet is currently marketed by the Company's marketing partner, Berlex Laboratories ("Berlex"). Although Cytogen believes that Berlex is an advantageous partner, there can be no assurance that Quadramet will achieve greater market penetration on a timely basis or result in significant revenues for Cytogen.

License and contract revenues for the second quarter of 2002 were \$65,000 compared to \$257,000 for the same period of 2001. As a result of the Company's adoption of Securities and Exchange Commission's Staff Accounting Bulletin No.101 (SAB 101) in 2000, license revenues include the recognition of deferred revenues from certain up-front, non-refundable license fees previously recognized in prior years. License and contract revenues have fluctuated in the past and will continue to fluctuate in the future.

Operating Expenses. Total operating expenses for the second quarter of 2002 were \$6.4 million compared to \$6.1 million recorded in the same quarter of 2001. The increase from the prior year period is attributable primarily to increased product costs related to higher product sales and increased development costs associated with PSMA Development Company LLC, a joint venture between Cytogen and Progenics Pharmaceuticals, Inc. ("Progenics") for the development of in vivo immunotherapies utilizing prostate specific membrane antigen, or PSMA. The increase is partially reduced by decreased research and development expenses related to the signal transduction research activities at AxCell and the development of a new manufacturing and purification process for ProstaScint.

Cost of product for the second quarter of 2002 was \$1.2 million compared to \$644,000 recorded in the same period of 2001. The increase from the prior year period is primarily due to the increase in sales of our BrachySeed products which carry a lower margin and a \$140,000 charge to reserve for excess inventory for ProstaScint, partially offset by lower facility related costs associated with the manufacturing of ProstaScint.

Research and development expenses for the second quarter of 2002 were \$1.7 million compared to \$2.5 million recorded in the same period of 2001. The decrease from the prior year period is attributable primarily to decreased costs associated with the AxCell's signal transduction inhibitors research programs and the development of a new manufacturing and purification process for ProstaScint. During the second quarters of 2002 and 2001, the Company invested \$1.0 million and \$1.2 million, respectively, in AxCell's signal transduction research activities, and \$352,000 and \$856,000, respectively, in the development of a new manufacturing process for ProstaScint. The Company is exploring strategic alternatives for AxCell, that would allow the Company to reduce its cash expenditures relating to AxCell in order to leverage its oncology franchise. Funding for the development of a new manufacturing process for ProstaScint has been put on hold pending further evaluation of the development results.

The Company's share in the equity loss in the PSMA Development LLC, our joint venture with Progenics Pharmaceuticals, Inc., was \$595,000 during the second quarter of 2002 and represented 50% of the Joint Venture's operating results. The Joint Venture is equally owned by Cytogen and Progenics and the Company accounts for the Joint Venture using the equity method of accounting. Progenics was obligated to fund the initial \$3.0 million of development costs of the Joint Venture. Beginning in December 2001, the Company and Progenics began to equally share the costs of the Joint Venture. The Company expects to incur significant costs in the future to fund its share of the development costs from the Joint Venture.

Selling and marketing expenses were \$1.6 million for each second quarter in 2001 and 2002. These expenses reflects costs associated with the launches of BrachySeed I-125 in 2001 and BrachySeed Pd-103 in 2002.

General and administrative expenses for the second quarter of 2002 were \$1.2 million compared to \$1.3 million for the comparable period in 2001. The decrease from the prior year period is due primarily to decreased spending in legal and professional fees.

Interest Income/Expense. Interest income for the second quarter of 2002 was \$72,000 compared to \$156,000 recorded in the same period of 2001. The decrease from the prior year period is due to a lower average yield on investments during 2002. Interest expense for the second quarter of 2002 was \$42,000 compared to \$44,000 recorded in the same period of 2001. The interest expenses included finance charges related with various equipment leases.

Net Loss. Net loss for the second quarter of 2002 was \$3.2 million compared to \$3.1 million reported in the second quarter of 2001. The net loss per share for the second quarter of 2002 was \$0.04 based on weighted average common shares outstanding of 83.1 million compared to a net loss per share of \$0.04 based on the weighted average common shares outstanding of 77.4 million for the same period in 2001.

Edgar Filing: CYTOGEN CORP - Form 10-Q

Six months ended June 30, 2002 and 2001

Revenues. Total revenues for the first half of 2002 and 2001 were \$6.5 million and \$5.9 million, respectively. The increase from the prior year period is due to higher product related revenues, partially offset by lower license and contract revenues. Product related revenues, which included product sales and royalties, accounted for 96% of total revenues in 2002 compared to 92% from the comparable period of 2001. License and contract revenues accounted for the remainder of revenues. For the fiscal year 2002, the Company projects total revenues to be in the range of \$12.5 million to \$14.5 million.

Product related revenues for the first half of 2002 and 2001 were \$6.2 million and \$5.4 million, respectively. Sales of ProstaScint accounted for 65% and 75% of product related revenues in the first half of 2002 and 2001, respectively, while Quadramet royalties accounted for 16% and 19% of product related revenues for such periods, respectively. Sales of ProstaScint were \$4.0 million for each of the first half of 2001 and 2002. Future growth of ProstaScint is dependent upon increased marketing and sales initiatives by Cytogen's in-house sales force, entry in additional markets and the implementation of new product applications, such as using ProstaScint scans to guide the placement of brachytherapy seeds and/or external beam radiation. There can be no assurance, however, that such initiatives will significantly increase the sales of ProstaScint. Royalties from Quadramet were \$1.0 million for each of the first half of 2001 and 2002. Quadramet royalties are based on net sales of Quadramet by Berlex.

Sales of BrachySeed for the first half of 2002 were \$1.0 million and accounted for 16% of product related revenues, compared to \$104,000 recorded in the same period of 2001. The increase from prior year period is due to increased market penetration of BrachySeed I-125 since its market introduction in February 2001, and to the initial sale of BrachySeed Pd-103, which was launched in May 2002. Sales of BrachySeed Pd-103 have not been substantial to date, since the product is still in the initial launch phase. There can be no assurance, however, as to the market acceptance of BrachySeed I-125 and Pd-103 or whether the sale of these products will significantly increase the revenues of the Company.

Sales of OncoScint CR/OV were \$110,000 in 2002 compared to \$225,000 in the same period of 2001. The market for OncoScint CR/OV for colorectal cancer diagnosis has been negatively affected by positron emission tomography or "PET" scans which have shown the same or higher sensitivity than OncoScint CR/OV. Accordingly, the Company is decreasing its emphasis on OncoScint in order to focus on its prostate cancer products.

License and contract revenues for the first half of 2002 and 2001 were \$280,000 and \$472,000, respectively. As a result of the Company's adoption of SAB 101 in 2000, license revenues for both 2002 and 2001 include the recognition of deferred revenues from certain up-front non-refundable license fees previously recognized in prior years.

Operating Expenses. Total operating expenses for the first half of 2002 were \$14.7 million compared to \$11.9 million recorded in 2001. The increase from the prior year period is attributable primarily to a one-time, non-cash milestone of \$2.0 million related to the progress of the dendritic cell prostate cancer clinical trials at Northwest Biotherapeutics, Inc. ("Northwest") and to increased development costs associated with the PSMA Development Company LLC.

Edgar Filing: CYTOGEN CORP - Form 10-Q

For fiscal year 2002, the Company projects total operating expenses, excluding cost of sales and one-time non-cash charges, to be in the range of \$20.0 million to \$22.0 million.

Cost of product for the first half of 2002 was \$2.3 million compared to \$1.8 million in the same period of the prior year. The increase from the prior year period is due primarily to the increase in sales of our BrachySeed products, which carry a lower margin and to a \$157,000 charge to reserve for excess inventory for OncoScint and ProstaScint, partially reduced by lower facility related costs associated with the manufacturing of ProstaScint.

Research and development expenses for the first half of 2002 were \$5.5 million compared to \$4.2 million recorded in the same period of 2001. The increase from the prior year period is attributable primarily to a one-time, non-cash milestone of \$2.0 million related to the progress of dendritic cell prostate cancer clinical trials at Northwest, partly offset by decreased costs associated with the AxCell's signal transduction inhibitors research programs and the development of a new manufacturing and purification process for ProstaScint. During the first six months of 2002 and 2001, the Company invested \$2.3 million and \$2.4 million, respectively, in AxCell's signal transduction research activities, and \$583,000 and \$900,000 respectively, in the development of a new manufacturing process for ProstaScint. The Company is exploring strategic alternatives for AxCell, that would allow the Company to reduce its cash expenditures relating to AxCell in order to leverage its oncology franchise. Funding for the development of a new purification and manufacturing process for ProstaScint has been put on hold pending further evaluation of the development results.

The Company's share in the equity loss in the PSMA Development LLC, our joint venture with Progenics Pharmaceuticals, Inc., was \$1.1 million during the first half of 2002 and represented 50% of the Joint Venture's operating results. The Joint Venture is equally owned by Cytogen and Progenics and the Company accounts for the Joint Venture using the equity method of accounting. Progenics was obligated to fund the initial \$3.0 million of development costs of the Joint Venture. Beginning in December 2001, the Company and Progenics began to equally share the costs of the Joint Venture. The Company expects to incur significant costs in the future to fund its share of the development costs from the Joint Venture (see Note 2 to the Consolidated Financial Statements).

Selling and marketing expenses were \$3.1 million for the first half of 2002 compared to \$3.3 million in the same period of 2001. The decrease from the prior year period is due primarily to the 2001 launch of BrachSeed I-125.

General and administrative expenses for the first half of 2002 were \$2.7 million compared to \$2.5 million for the comparable period in 2001. The increase from the prior year period is due in part to stock based compensation for a key employee.

Interest Income/Expense. Interest income for the first half of 2002 was \$149,000 compared to \$377,000 recorded in the same period of 2001. The decrease from the prior year period is due a lower average yield on investments in 2002. Interest expense for the first half of 2002 was \$84,000 compared to \$92,000 recorded in the same period of 2001. The interest expenses included finance charges related with various equipment leases.

Net Loss. Net loss for the first half of 2002 was \$8.2 million compared to \$5.7 million recorded in the same period of 2001. The net loss per share for the

Edgar Filing: CYTOGEN CORP - Form 10-Q

first half of 2002 was \$0.10 based on weighted average common shares outstanding of 82.2 million compared to a net loss per share of \$0.07 based on the weighted average common shares outstanding of 76.8 million for the same period in 2001. The 2002 net loss included a one-time, non-cash milestone of \$2.0 million related to the progress of dendritic cell prostate cancer clinical trials at Northwest.

Liquidity and Capital Resources

The Company's cash and cash equivalents were \$18.9 million as of June 30, 2002, compared to \$11.3 million as of December 31, 2001. The cash used for operating activities for the six months ended June 30, 2002 was \$4.9 million compared to \$7.1 million in the same period of 2001. The decrease from the prior year period is due primarily to the improved working capital management and to the build-up of ProstaScint inventory in 2001 as the Company is in the process of seeking a new manufacturer of ProstaScint. For fiscal year 2002, the Company projects that cash used in operations will be in the range of \$9.5 million to \$10.5 million.

Historically, the Company's primary sources of cash have been proceeds from the issuance and sale of its stock through public offerings and private placements, product related revenues, revenues from contract manufacturing and research services, fees paid under license agreements and interest earned on cash and short-term investments.

The Company filed a shelf Registration Statement on Form S-3 to register 10,000,000 shares of its common stock in October 2001. Such Registration Statement was declared effective by the Securities and Exchange Commission in November 2001. The Company may issue such registered shares of common stock from time to time and may use the proceeds thereof for general corporate purposes, including, but not limited to, continued development and commercialization of its proteomics technologies, research and development of additional products and expansion of its sales and marketing capabilities. As of June 30, 2002 the Company has registered 7,137,365 shares of common stock under such shelf registration statement and a total of 2,862,635 shares of the Company's common stock remain available to be registered.

In January 2002, the Company sold 2,970,665 shares of Cytogen common stock to the State of Wisconsin Investment Board ("SWIB") for an aggregate purchase price of \$8.0 million or \$2.69 per share. In June 2002, the Company sold an additional 4,166,700 shares of Cytogen common stock for an aggregate purchase price of \$5.0 million or \$1.20 per share. Pursuant to its agreement with SWIB, in January 2002 the Company agreed not to enter into equity line arrangements in the future, issue certain securities at less than fair market value or undertake certain other securities issuances without requisite stockholder approval.

On June 18, 2002, the Company received approval from the stockholders of the Company at the Company's Annual Meeting to amend the Company's By-Laws, the 1995 Stock Option Plan and the 1999 Non-Employee Director Plan to effect such restrictions imposed pursuant to the SWIB financings.

In January 2002, the Company received cash of \$1.1 million relating to the December 2001 sale of New Jersey State net operating losses and research and development credits. Under the current legislation, the Company may be able to

sell a minimum \$634,000 of its remaining approved \$2.4 million of tax benefits

Edgar Filing: CYTOGEN CORP - Form 10-Q

in 2002 assuming the State of New Jersey continues to fund this program. The actual amount of net operating losses and tax credits the Company may sell will also depend upon the allocation among qualifying companies of an annual pool established by the State of New Jersey.

Beginning in December 2001, Cytogen and Progenics began to equally share the costs of the Joint Venture. Since that date, Cytogen has recognized 50% of the Joint Venture's operating results, which, during the first half of 2002 was a loss of \$1.1 million. The Company expects its share of losses in the PSMA Development Co. LLC to continue at even higher levels in subsequent periods.

The Company's capital and operating requirements may change depending upon various factors, including: (i) whether the Company and its strategic partners achieve success in manufacturing, marketing and commercialization of its products; (ii) the amount of resources which the Company devotes to clinical evaluations and the expansion of marketing and sales capabilities; (iii) results of clinical trials and research and development activities; and (iv) competitive and technological developments, in particular, the Company expects to incur significant costs for the development of its proteomics and PSMA technologies.

The Company's financial objectives are to meet its capital and operating requirements through revenues from existing products and licensing arrangements. To achieve its strategic objectives, the Company may enter into research and development partnerships and acquire, in-license and develop other technologies, products or services. Certain of these strategies may require payments by the Company in either cash or stock in addition to the costs associated with developing and marketing a product or technology. There can be no assurance as to the success of such strategies or that resulting funds will be sufficient to meet cash requirements until such time as product revenues are sufficient to cover operating expenses, if ever. To fund these strategic and operating activities, the Company may sell assets, equity or debt securities as market conditions permit or enter into credit facilities.

The Company has incurred negative cash flows from operations since its inception, and has expended, and expects to continue to expend in the future, substantial funds to implement its planned product development efforts, including acquisition of products and complementary technologies, research and development, clinical studies and regulatory activities, and to further its marketing and sales programs. The Company expects that its existing capital resources should be adequate to fund the Company's operations during 2003. The Company cannot assure you that its business or operations will not change in a manner that would consume available resources more rapidly than anticipated. The Company expects that it will have additional requirements for capital from the issuance of debt or equity securities, irrespective of whether and when it reaches profitability, for further product development costs, product and technology acquisition costs, and working capital.

The Company's future capital requirements and the adequacy of available funds will depend on numerous factors, including the successful commercialization of its products, the costs associated with the acquisition of complementary products and technologies, progress in its product development efforts, the magnitude and scope of such efforts, progress with clinical trials, progress with regulatory affairs activities, the cost of filing, prosecuting,

defending and enforcing patent claims and other intellectual property rights, competing technological and market developments, and the expansion of strategic alliances for the sales, marketing, manufacturing and distribution of its

Edgar Filing: CYTOGEN CORP - Form 10-Q

products. To the extent that the currently available funds and revenues are insufficient to meet current or planned operating requirements, the Company will be required to obtain additional funds through asset sales, equity or debt financing, strategic alliances with corporate partners and others, or through other sources. There can be no assurance that the financial sources described above will be available when needed or at terms commercially acceptable to the Company. If adequate funds are not available, the Company may be required to delay, further scale back or eliminate certain aspects of its operations or attempt to obtain funds through arrangements with collaborative partners or others that may require the Company to relinquish rights to certain of its technologies, product candidates, products or potential markets. If adequate funds are not available, the Company's business, financial condition and results of operations will be materially and adversely affected.

CRITICAL ACCOUNTING POLICIES

Financial Reporting Release No. 60, which was recently released by the Securities and Exchange Commission, requires all companies to include a discussion of critical accounting policies or methods used in the preparation of financial statements. Note 1 to our Consolidated Financial Statements in this Quarterly Report on Form 10-Q and Note 1 to our Consolidated Financial Statements in the Company's Annual Report on Form 10-K for the year ended December 31, 2001, include a summary of our significant accounting policies and methods used in the preparation of our Consolidated Financial Statements. The following is a brief discussion of the more significant accounting policies and methods used by us. The preparation of our Consolidated Financial Statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Our actual results could differ from those estimates.

Revenue Recognition

We recognize revenue from the sale of our products upon shipment. We do not grant price protection to customers. Quadramet royalties are recognized when earned. The Securities and Exchange Commission has issued Staff Accounting Bulletin (SAB) No. 101, "Revenue Recognition", which provides guidance on the recognition of up-front, non-refundable license fees. Accordingly, we defer up-front license fees and recognize them over the estimated performance period of the related agreement, when we have continuing involvement. Since the term of the performance periods is subject to management's estimates, future revenues to be recognized could be affected by changes in such estimates.

Accounts Receivable

Our accounts receivable balances are net of an estimated allowance for uncollectible accounts. We continuously monitor collections and payments from our customers and maintain an allowance for uncollectible accounts based upon our historical experience and any specific customer collection issues that we have identified. While we believe our reserve estimate to be appropriate, we may find it necessary to adjust our allowance for doubtful accounts if our future

bad debt expense exceeds our estimated reserve. We are subject to concentration risks as a limited number of our customers provide a high percent of total revenues, and corresponding receivables.

Edgar Filing: CYTOGEN CORP - Form 10-Q

Inventories

Inventories are stated at the lower of cost or market, as determined using the first-in, first-out method, which most closely reflects the physical flow of our inventories. Our products and raw materials are subject to expiration dating. We regularly review quantities on hand to determine the need for reserves for excess and obsolete inventories based primarily on our estimated forecast of our product sales. Our estimate of future product demand may prove to be inaccurate, in which case we may have understated or overstated our reserve for excess and obsolete inventories.

Carrying Value of Fixed and Intangible Assets

Our fixed assets and certain of our acquired rights to market our products have been recorded at cost and are being amortized on a straight-line basis over the estimated useful life of those assets. If indicators of impairment exist, we assess the recoverability of the affected long-lived assets by determining whether the carrying value of such assets can be recovered through undiscounted future operating cash flows. If impairment is indicated, we measure the amount of such impairment by comparing the carrying value of the assets to the present value of the expected future cash flows associated with the use of the asset. Adverse changes regarding future cash flows to be received from long-lived assets could indicate that an impairment exists, and would require the write down of the carrying value of the impaired asset at that time.

Item 3 - Quantitative and Qualitative Disclosures About Market Risk

The Company does not have operations subject to risks of foreign currency fluctuations, nor does it use derivative financial instruments in its operations or investment portfolio. The Company does not have exposure to market risks associated with changes in interest rates, as it has no variable interest rate debt outstanding. The Company does not believe it has any other material exposure to market risks associated with interest rates.

18

PART II - OTHER INFORMATION

Item 4 - Submission of Matters to the Vote of Security Holders

On June 18, 2002, the Company held its annual meeting of stockholders to (i) elect six directors; (ii) to consider and vote upon a proposal to amend, as required, the Company's 1995 Stock Option Plan, 1999 Non-Employee Director Stock Option Plan and By-Laws, as applicable, to provide that without the approval of a majority of the Company's stockholders, the Company shall not: (a) grant stock appreciation rights with an exercise price that is less than the fair market value of the underlying common stock; or (b) effectively amend or replace certain outstanding equity-based awards in a manner that would result in lower exercise prices, accelerated vesting schedules or the issuance of restricted stock; and (iii) transact such other business as might be brought up before the meeting.

The following tables set forth information regarding the number of votes cast for, against or withheld, abstentions and broker non-votes, with respect to each matter presented at the meeting. Under the rules of the Nasdaq Stock Market, brokers who hold shares in street name for customers who are beneficial owners of those shares may be prohibited from giving a proxy to vote shares held for such customers on certain

Edgar Filing: CYTOGEN CORP - Form 10-Q

matters without specific instructions from such customers (broker non-votes). Under Delaware law, abstentions and broker non-votes are counted as shares represented at the meeting for purposes of determining the presence or absence of a quorum at a stockholders meeting. The election of directors is decided by a plurality of the votes cast. Therefore, votes that are withheld have no effect on the outcome of the vote. Adoption of the remaining proposal required the affirmative vote of a majority of shares cast at the meeting. Therefore, abstentions and broker non-votes have no effect on the vote.

(i) Election of Directors:

Nominee -----	For ---	Against or Withheld -----	Abstentions -----	Broker Non-Votes -----
John E. Bagalay Jr.	74,300,649	3,406,760	N/A	N/A
Stephen K. Carter	76,070,588	1,636,821	N/A	N/A
James A. Grigsby	75,784,639	1,922,770	N/A	N/A
Robert F. Hendrickson	65,408,808	12,298,601	N/A	N/A
Kevin G. Lokay	65,455,560	12,251,849	N/A	N/A
H. Joseph Reiser	76,224,110	1,483,299	N/A	N/A

(ii) Proposal to amend, as required, the Company's 1995 Stock Option Plan, 1999 Non-Employee Director Stock Option Plan and By-Laws, as applicable, to provide that without the approval of a majority of the Company's stockholders, the Company shall not: (a) grant stock appreciation rights with an exercise price that is less than the fair market value of the underlying common stock; or (b) effectively amend or replace certain outstanding equity-based awards in a manner that would result in lower exercise prices, accelerated vesting schedules or the issuance of restricted stock.

19

For ---	Against or Withheld -----	Abstentions -----	Broker Non-Votes -----
74,495,767	2,807,028	404,614	N/A

Item 6 - Exhibits and Reports on Form 8-K

(a) Exhibits:

10.1 - Sublease Agreement by and between Cytogen Corporation and Hale and Dorr, LLP dated as of May 23, 2002. Filed herewith.

10.2 - Addendum to Stock Exchange Agreement among Cytogen Corporation and the Shareholders and Debt holders of Prostagin, Inc. dated as of May 14, 2002, and amended as of August 13, 2002. Filed herewith.

99.1 - Certification of Disclosure on Form 10-Q for the period ended June 30, 2002 by H. Joseph Reiser, President and Chief Executive Officer of Cytogen Corporation. Filed herewith.

Edgar Filing: CYTOGEN CORP - Form 10-Q

99.2 - Certification of Disclosure on Form 10-Q for the period ended June 30, 2002 by Lawrence R. Hoffman, Vice President and Chief Financial Officer of Cytogen Corporation. Filed herewith.

(b) Reports on Form 8-K

During the three months ended June 30, 2002, the Company filed with the Securities and Exchange Commission four Current Report on Form 8-K and Form 8-K/A. The Form 8-K and Form 8-K/A dated May 20, 2002, reported on "Item 4. Changes in Registrant's Certifying Accountant" the change of the Company's independent public accountants to KPMG LLP for the fiscal year ending December 31, 2002 replacing Arthur Andersen LLP, effective immediately. The Form 8-K dated May 29, 2002, reported on "Item 5. Other Events" the followings: i) Cytogen's launch of Draxis Health's BrachySeed Palladium Pd-103 product in the United States for the treatment of prostate cancer and ii) the Company's financial guidance and strategic planning and operation for 2002. The Form 8-K dated June 4, 2002, reported on "Item 5. Other Events" the sale of 4,166,700 shares of Cytogen common stock to The State of Wisconsin Investment Board for an aggregate purchase price of approximately \$5.0 million on June 4, 2002.

20

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

CYTOGEN CORPORATION

Date August 14, 2002

By: /s/ H. Joseph Reiser

H. Joseph Reiser
President and Chief Executive Officer

Date August 14, 2002

By /s/ Lawrence R. Hoffman

Lawrence R. Hoffman
Vice President and Chief Financial Officer
(Principal Financial and Accounting Officer)

